OTTAWA, March 25
/PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS;
http://www.htdsmedical.com/) Further to the previously announced
cosmetics merger (press release Feb 25,
2010) between Melem Secret's and Collagenna Skin Care
Products, the company has decided to develop its neutraceutical
business of supplements and natural health products under the Melem
Secret brand.
Collagenna's CEO Michael Arnkvarn
states: "We have been promoting a few supplements for optimal skin
care but we have identified several other health products which we
would like to bring to market. We feel that we need to create a
brand independent of our skin care line. The Melem Secret brand
will focus mainly on supplements and natural health products and
Collagenna will continue its Skin Care brand."
New packaging is being developed along with a total revamp of
the website www.melemsecret.com to reflect this new direction.
Melem Secret has retained the services of a professional internet
marketer in order to jump start the marketing efforts of the new
brand. The new brand launch is expected to start in about 15-30
days and it will feature the introduction of Melem Secret's new
Baobab supplement. This product originates from Africa and has mainly highly attractive health
benefits: high antioxidant value, high source of calcium, rich in
iron, potassium, magnesium and Vitamin C.
Other products that are ready to be marketed by Melem Secret
include Marine Collagen Capsules, Omega 3 gel capsules as well as
the Skin Defense Complex Caps.
The company reminds its shareholders and followers to monitor
PinkSheets.com Filing section and also our IR company web site
section "PRESS RELEASES AND FILINGS" TAB
http://www.minamargroup.net/ for non newsworthy corporate
updates.
For any matters relating to retail investor queries or to send
the company or its IR a message please click on the "INVESTOR
SUPPORT" TAB, or the direct link
http://www.minamargroup.net/helpdesk.
Don't be a victim. Report a stock basher. The company is mindful
that short sellers, the company competitors and stock bashers stalk
small cap Pink Sheets listed companies with hidden agendas. Visit
http://www.stockbasher.com/ and find out what criminal and civil
actions the US authorities are taking against web sites like
investorshub.com and other posters, and the remedies available to
you as an individual investor.
Filings for this event are currently being reviewed and will be
filed with Pink Sheets and Client Support section in due course. To
be included in company's email database for press releases,
industry updates, and non-weekly activity in the company that may
or may not be news released, please subscribe or opt in mailer at
http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future
expectations, plans, prospects or performance of Hard to Treat
Diseases, Inc. that constitute forward-looking statements for
purposes of the safe harbor Provisions under the Private Securities
Litigation Reform Act of 1995. The words or phrases "can be,"
"expects," "may affect," "believed," "estimate," "project," and
similar words and phrases are intended to identify such
forward-looking statements. HTDS Corporation cautions you that any
forward-looking information provided by or on behalf of Hard to
Treat Diseases, Inc. is not a guarantee of future performance. None
of the information in this filing constitutes or is intended as an
offer to sell securities or investment advice of any kind. Hard to
Treat Diseases, Inc.'s actual results may differ materially from
those anticipated in such forward-looking statements as a result of
various important factors, some of which are beyond Hard to Treat
Diseases, Inc.'s control. In addition to those discussed in Hard to
Treat Diseases, Inc.'s press releases, public filings, and
statements by Hard to Treat Diseases, Inc.'s management, including,
but not limited to, Hard to Treat Diseases, Inc.'s estimate of the
sufficiency of its existing capital resources, Hard to Treat
Diseases, Inc.'s ability to raise additional capital to fund future
operations, HTDS Corporation's ability to repay its existing
indebtedness, the uncertainties involved in estimating market
opportunities and, in identifying contracts which match Hard to
Treat Diseases, Inc.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which
such statements were made. Hard to Treat Diseases, Inc. does not
undertake any obligation to publicly update any forward-looking
statement to reflect events or circumstances after the date on
which any such statement is made or to reflect the occurrence of
unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only,
please contact medicalinfo@htdsmedical.com; For any corporate
matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases